Furthermore, p53 mutations can support immune dysfunction by altering the tumor microenvironment, disrupting innate immunity by modulating the TLR signaling pathway, and promoting immune privilege and the ability to survive by disrupting cell-mediated immunity (Agupitan et al., 2020). This evidence concerns the gene TP53 and neoplasm.